Glass C K, Pittman R C, Keller G A, Steinberg D
J Biol Chem. 1983 Jun 10;258(11):7161-7.
The tissue sites of degradation of apoprotein A-I were determined in the rat in vivo using a newly developed tracer of protein catabolism, an adduct of 125I-tyramine and cellobiose. This methodology takes advantage of the fact that when a protein labeled with 125I-tyramine-cellobiose is taken up and degraded, the radiolabeled ligand remains trapped intracellularly. Thus, radio-iodine accumulation in a tissue acts as a cumulative measure of protein degradation in that tissue. In the present studies, apoprotein AI (apo-A-I) was labeled with tyramine-cellobiose (TC). The TC-labeled apo-A-I was then reassociated with high density lipoprotein (HDL) in vivo by injection into donor animals. After 30 min, serum from donor animals was recovered and then injected into recipient rats. TC-labeled apo-A-I in the donor serum was shown to be exclusively associated with HDL. The fractional catabolic rate of 125I-TC-apo-A-I was not significantly different from that of conventionally labeled apo-A-I. The kidney was the major site of degradation, accounting for 39% of the total. The liver was responsible for 26% of apo-A-I catabolism, 96% of which occurred in hepatocytes. The kidney was also the most active organ of catabolism/g of wet weight. The tissues next most active/g of wet weight were ovary and adrenal, a finding that is compatible with a special role of HDL in the rat for delivery of cholesterol for steroidogenesis. Immunofluorescence studies of frozen sections of rat kidney demonstrated the presence of apo-A-I on the brush-border and in apical granules of proximal tubule epithelial cells. Preliminary studies using HDL labeled both with 125I-TC-apo-A-I and [3H]cholesteryl ethers again demonstrated high rates of renal uptake of apo-A-I but less than 1% of total ether uptake. It is postulated that the high activity of kidney was not due to uptake of intact HDL particles, but rather, due to glomerular filtration and tubular reabsorption of free apo-A-I.
使用一种新开发的蛋白质分解代谢示踪剂——125I-酪胺与纤维二糖的加合物,在大鼠体内确定了载脂蛋白A-I的降解组织部位。该方法利用了这样一个事实:当用125I-酪胺-纤维二糖标记的蛋白质被摄取并降解时,放射性标记的配体仍被困在细胞内。因此,组织中放射性碘的积累可作为该组织中蛋白质降解的累积指标。在本研究中,载脂蛋白AI(apo-A-I)用酪胺-纤维二糖(TC)进行标记。然后通过注射到供体动物体内,使TC标记的apo-A-I在体内与高密度脂蛋白(HDL)重新结合。30分钟后,收集供体动物的血清,然后注射到受体大鼠体内。结果显示,供体血清中TC标记的apo-A-I仅与HDL相关。125I-TC-apo-A-I的分解代谢率与传统标记的apo-A-I没有显著差异。肾脏是主要的降解部位,占总量的39%。肝脏负责apo-A-I分解代谢的26%,其中96%发生在肝细胞中。肾脏也是每克湿重分解代谢最活跃的器官。每克湿重其次最活跃的组织是卵巢和肾上腺,这一发现与HDL在大鼠体内为类固醇生成输送胆固醇的特殊作用相符。对大鼠肾脏冰冻切片的免疫荧光研究表明,近端小管上皮细胞的刷状缘和顶端颗粒中存在apo-A-I。使用125I-TC-apo-A-I和[3H]胆固醇醚标记的HDL进行的初步研究再次表明,肾脏对apo-A-I的摄取率很高,但占总醚摄取量的不到1%。据推测肾脏的高活性不是由于完整HDL颗粒的摄取,而是由于游离apo-A-I的肾小球滤过和肾小管重吸收。